Artelo Biosciences (ARTL) Common Equity (2014 - 2025)

Artelo Biosciences (ARTL) has reported Common Equity for 12 consecutive years, with $166.7 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Common Equity rose 5733.63% year-over-year to $166.7 million in Q4 2025; TTM through Dec 2025 was $166.7 million, a 5733.63% increase from a year earlier, with the FY2025 full-year figure at $166.7 million, up 5733.63% from the prior year.
• Common Equity was $166.7 million for Q4 2025 at Artelo Biosciences, up from -$633000.0 in the prior quarter.
• Over five years, Common Equity peaked at $166.7 million in Q4 2025 and troughed at -$1.4 million in Q2 2025.
• A 5-year average of $20.4 million and a median of $12.4 million in 2021 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 5733.63% in 2025, down 119.26% in 2025.
• Over 5 years, Common Equity stood at $28.3 million in 2021, then slumped by 31.4% to $19.4 million in 2022, then plunged by 39.43% to $11.8 million in 2023, then plunged by 75.69% to $2.9 million in 2024, then jumped by 5733.63% to $166.7 million in 2025.
• The last three Common Equity figures came in at $166.7 million (Q4 2025), -$633000.0 (Q3 2025), and -$1.4 million (Q2 2025), per Business Quant data.